Search results for "Hormone replacement therapy"

showing 10 items of 72 documents

Muscular transcriptome in postmenopausal women with or without hormone replacement.

2007

The loss of muscle mass and strength with aging is well characterized, but our knowledge of the molecular mechanisms underlying the development of sarcopenia remains incomplete. Although menopause is often accompanied with first signs of age-associated changes in muscle structure and function, the effects of hormone replacement therapy (HRT) or menopause-related decline in estrogen production in the muscles of postmenopausal women is not well understood. Furthermore the knowledge of the global transcriptional changes that take place in skeletal muscle in relation to estrogen status has thus far been completely lacking. We used a randomized double-blinded study design together with an explor…

Agingmedicine.medical_specialtyvaihdevuodetmedicine.drug_classmenopaussiBiologysarcopeniaTranscriptomeInternal medicinemedicineHumanssarkopeniaRNA Messengermuscular transcriptomeMuscle SkeletalOligonucleotide Array Sequence AnalysishormonikorvaushoitolihastranskriptomiRegulation of gene expressionPostmenopausal womenGene Expression ProfilingEstrogen Replacement TherapySkeletal muscleMiddle Agedmedicine.diseaseMenopauseGene expression profilingPostmenopausehormone replacement therapyEndocrinologymedicine.anatomical_structureGene Expression RegulationReceptors EstrogenEstrogenSarcopeniaFemalesense organsGeriatrics and GerontologyRejuvenation research
researchProduct

Apo E phenotypes and plasma triglycerides in postmenopausal women with hormone replacement therapy

2000

Apolipoprotein Emedicine.medical_specialtyEndocrinologyPostmenopausal womenbusiness.industryInternal medicinemedicineHormone replacement therapyCardiology and Cardiovascular MedicinebusinessPhenotypeAtherosclerosis
researchProduct

Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth h…

2014

Purpose: To evaluate the performance of various indexes of insulin sensitivity and secretion and to identify the most useful indicator of deterioration of glucose metabolism in a cohort of children with growth hormone (GH) deficiency (GHD) during GH treatment. Methods: In 73 GHD children (55 M, 18 F; mean age 10.5 years) at baseline and after 12 months of treatment, we evaluated a number of surrogate indexes of insulin secretion and sensitivity. In a subgroup of 11 children we also performed an euglycemic hyperinsulinemic clamp. Results: After 12 months, a significant increase in fasting glucose (p < 0.001) and HbA1c levels (p < 0.001) was documented, despite all children remained with a no…

Blood GlucoseMalemedicine.medical_specialtyAdolescentHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentChildren; Glucose metabolism; Growth hormone treatment; Insulin secretion; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyHypopituitarismCarbohydrate metabolismHypopituitarismSettore MED/13 - EndocrinologiaEndocrinologyInsulin resistanceInsulin-Secreting CellsInternal medicinemedicineHormone replacement therapy (male-to-female)HumansInsulinGrowth hormone treatmentChildDwarfism PituitaryChildrenGlucose metabolismGlucose tolerance testmedicine.diagnostic_testHuman Growth Hormonebusiness.industryInsulin secretionInsulinGlucose Tolerance TestInsulin sensitivitymedicine.diseaseGrowth hormone treatmentTreatment OutcomeEndocrinologyChild PreschoolConcomitantFemaleInsulin Resistancebusiness
researchProduct

The mechanisms of thrombotic risk induced by hormone replacement therapy.

2001

Abstract Objective : To review the available information on the action of hormones on the mechanisms involved in thrombotic risk. Results and Conclusions : Thrombosis plays a crucial role in the genesis and progression of both coronary heart disease (CHD) and venous thromboembolic disease (VTED), the two main forms of cardiovascular disease. Two main determinants of the thromboembolic phenotype, hypercoagulable state and altered endothelium, accumulate much of the work performed on the influence of hormones on thrombosis. Information has accumulated mainly for oestrogens, but increasing evidences support a role for progestogens. The sensitivity of each of the three components of the hemosta…

Blood PlateletsMalemedicine.medical_specialtyArteriosclerosismedicine.medical_treatmentCoronary DiseaseDiseaseBioinformaticsFibrinogenGeneral Biochemistry Genetics and Molecular Biologychemistry.chemical_compoundRisk FactorsInternal medicineFibrinolysismedicineHumansHormone replacement therapyEndothelial dysfunctionAgedVenous ThrombosisHemostasisFactor VIIbusiness.industryAntithrombinEstrogen Replacement TherapyObstetrics and GynecologyEstrogensMiddle Agedmedicine.diseasePostmenopauseEndocrinologyPhenotypechemistryHemostasisFemaleEndothelium Vascularbusinessmedicine.drugMaturitas
researchProduct

The effect of hormone replacement therapy on Ca2+ mobilization and P-selectin (CD62P) expression in platelets examined under flow cytometry.

2004

A series of events, such as increase of cytoplasmic free calcium (Ca 2+ ) and expression of P-selectin (CD62P), an adhesion molecule, on the platelet surface, are significant indicators of platelet activation. We have used flow cytometry to examine Ca 2+ mobilization and CD62P expression in platelets in whole blood obtained in women prior to, and after, different forms of hormone replacement therapy. Thirty-two women completed a protocol consisting of two consecutive 1-month periods under oestradlol (E 2 ), administered orally (2 mg/day) or transdermally (50 μg/day) in random order, followed by a 4-week transdermal sequential regime, in which, during the last 14 days, either progesterone (3…

Blood Plateletsmedicine.medical_specialtyCytoplasmP-selectinHormone Replacement Therapychemistry.chemical_compoundInternal medicinemedicineMedroxyprogesterone acetateHumansPlateletPlatelet activationWhole bloodTransdermalEstradiolHematologyGeneral MedicineMiddle AgedPlatelet ActivationAdenosine diphosphateP-SelectinEndocrinologychemistryGene Expression RegulationCalciumFemaleMenopauseHormonemedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women

2019

Aim: Use of menopausal hormone therapy (MHT) has been associated with a reduced risk for colorectal cancer, but mechanisms underlying this relationship are not well understood. In the colon, MHT appears to act through estrogen receptor β (ERβ) which may influence DNA methylation by binding to DNA. Using genome-wide methylation profiling data, we aimed to identify genes that may be differentially methylated according to MHT use. Materials &amp; methods: DNA methylation was measured using Illumina HumanMethylation450k arrays in two independent tumor sample sets of colorectal cancer patients. Differential methylation was determined using R/limma. Results: In the discovery analysis, two CpG si…

Cancer Researchmedicine.drug_classColorectal cancermedicine.medical_treatmentEstrogen receptorBiologychemistry.chemical_compoundGeneticsmedicineEstrogen Receptor betaHumansGeneAgedAged 80 and overEstrogen Replacement TherapyHormone replacement therapy (menopause)DNA MethylationMiddle Agedmedicine.diseasechemistryCpG siteEstrogenDNA methylationCancer researchCpG IslandsFemaleMenopauseColorectal NeoplasmsDNAEpigenomics
researchProduct

HERS study disturbs hormonal replacement therapy

2000

Cardiovascular protection of hormonal replacement therapy was considered a fact. The effects of estrogens on lipid levels and vascular health gave biological support to estrogen cardioprotection. The recently published HERS study showing no protective effects of estrogen and progesterone replacement therapy on the risk of myocardial infarction or coronary deaths is provoking perplexity. These surprising results may have several causes such as the use of progesterone, the associated use of cardioprotective agents or the short observation period. However, the study results scope is rectricted to secondary prevention. These cannot be extrapolated to frequent conditions of postmenopausal women …

CardioprotectionSecondary preventionmedicine.medical_specialtyPostmenopausal womenbusiness.industrymedicine.drug_classPhysiologyGeneral Medicinemedicine.diseaseVascular healthEndocrinologyCardiovascular diseasesHormone replacement therapyEstrogenInternal medicinePrimary preventionmedicineCardioprotective AgentMyocardial infarctionpost-menopausalEstrogen replacement therapybusiness
researchProduct

Ovarian tissue cryopreservation and transplantation in menopause: new perspective of therapy in postmenopausal women and the importance of ethical an…

2023

Menopausal transition entails a progressive decrease in hormone production by the ovaries that lead to important physical and psychological changes that could significantly affect quality of life. Hormone replacement therapy (HRT) administered from the onset of menopausal symptoms usually improves quality of life and life expectancy. Nevertheless, it is not risk-free. Ovarian tissue cryopreservation (OTC) has been investigated as a potential new strategy for delaying menopause and/or to avoid HRT. This review analyzes the critical points of HRT to assess whether OTC and subsequent reimplantation can affect postmenopausal management. We assessed available randomized clinical trials in PubMed…

CryopreservationCounselingTransplantationEstrogen Replacement TherapyEstrogensGuidelinesHormone replacement therapy (HRT)Settore MED/40 - Ginecologia E OstetriciaPostmenopauseOvarian tissue cryopreservation (OTC)Medicolegal viabilityQuality of LifeHumansOsteoporosisFemaleMenopause
researchProduct

Menopause and diabetes: EMAS clinical guide

2018

Abstract Introduction Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing has been a matter of debate. Controversy also exists about the benefits and risks of menopausal hormone therapy (MHT) in women with T2DM. Aims To summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM. Materials and methods Literature review and consensus of experts’ opinions. Results and conclusion Metabolic changes during the menopausal transition include an increase in and the central redis…

ESTROGEN REPLACEMENTmedicine.medical_specialtyHORMONE-REPLACEMENT THERAPYendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismDiseaseDydrogesteroneGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicine3123 Gynaecology and paediatricsRisk FactorsInternal medicineDiabetes mellitusType 2 diabetes mellitusDiabetes MellitusmedicineHumansNATURAL MENOPAUSEMenopausal hormone therapy; Menopause; Type 2 diabetes mellitus; Estrogen Replacement Therapy; Female; Humans; Incidence; Risk Factors; Diabetes Mellitus Type 2; MenopauseESTRADIOLMETABOLIC SYNDROME030219 obstetrics & reproductive medicineProgestogenINSULIN SENSITIVITYbusiness.industryIncidenceEstrogen Replacement TherapyENERGY-EXPENDITUREnutritional and metabolic diseasesObstetrics and GynecologyType 2 Diabetes MellitusHormone replacement therapy (menopause)medicine.disease3. Good healthMenopausePOSTMENOPAUSAL WOMENDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineRISK-FACTORSFemaleHEALTHMenopauseMetabolic syndromebusinessType 2Menopausal hormone therapymedicine.drug
researchProduct

Metabolic comorbidities of adrenal insufficiency: Focus on steroid replacement therapy and chronopharmacology

2021

Adrenal insufficiency (AI) is characterized by higher mortality and morbidity compared with the general population. Conventional replacement steroid therapy, currently recommended for the treatment of AI, is associated with increased frequency of metabolic comorbidities due to daily overexposure. By contrast, dual-release hydrocortisone is associated with a decreased risk of metabolic comorbidities, providing an adequate release of hydrocortisone and mimicking the physiological profile of cortisol. These favorable effects are due to a reduced daily steroid exposure that does not affect the expression of the clock genes which are involved in metabolic pathways and are regulated by the normal…

HydrocortisoneHormone Replacement Therapymedicine.medical_treatmentPopulationPhysiologyEndogenyComorbiditySettore MED/13 - EndocrinologiaSteroidGlucocorticoidDrug DiscoverymedicineAdrenal insufficiencyHumansCircadian rhythmeducationGlucocorticoidsHydrocortisonePharmacologyeducation.field_of_studybusiness.industrymedicine.diseaseCircadian RhythmCLOCKNarrative reviewbusinessHumanAdrenal Insufficiencymedicine.drugCurrent Opinion in Pharmacology
researchProduct